Literature DB >> 28521009

Toward more informative biomarker-based clinical trials in glioblastoma.

Howard Colman1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28521009      PMCID: PMC5570242          DOI: 10.1093/neuonc/nox063

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  10 in total

Review 1.  Adaptive clinical trials in oncology.

Authors:  Donald A Berry
Journal:  Nat Rev Clin Oncol       Date:  2011-11-08       Impact factor: 66.675

Review 2.  Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials.

Authors:  Jianchang Lin; Veronica Bunn
Journal:  Contemp Clin Trials       Date:  2017-01-13       Impact factor: 2.226

3.  Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Authors:  Hope S Rugo; Olufunmilayo I Olopade; Angela DeMichele; Christina Yau; Laura J van 't Veer; Meredith B Buxton; Michael Hogarth; Nola M Hylton; Melissa Paoloni; Jane Perlmutter; W Fraser Symmans; Douglas Yee; A Jo Chien; Anne M Wallace; Henry G Kaplan; Judy C Boughey; Tufia C Haddad; Kathy S Albain; Minetta C Liu; Claudine Isaacs; Qamar J Khan; Julie E Lang; Rebecca K Viscusi; Lajos Pusztai; Stacy L Moulder; Stephen Y Chui; Kathleen A Kemmer; Anthony D Elias; Kirsten K Edmiston; David M Euhus; Barbara B Haley; Rita Nanda; Donald W Northfelt; Debasish Tripathy; William C Wood; Cheryl Ewing; Richard Schwab; Julia Lyandres; Sarah E Davis; Gillian L Hirst; Ashish Sanil; Donald A Berry; Laura J Esserman
Journal:  N Engl J Med       Date:  2016-07-07       Impact factor: 91.245

4.  Adaptive Randomization of Neratinib in Early Breast Cancer.

Authors:  John W Park; Minetta C Liu; Douglas Yee; Christina Yau; Laura J van 't Veer; W Fraser Symmans; Melissa Paoloni; Jane Perlmutter; Nola M Hylton; Michael Hogarth; Angela DeMichele; Meredith B Buxton; A Jo Chien; Anne M Wallace; Judy C Boughey; Tufia C Haddad; Stephen Y Chui; Kathleen A Kemmer; Henry G Kaplan; Claudine Isaacs; Rita Nanda; Debasish Tripathy; Kathy S Albain; Kirsten K Edmiston; Anthony D Elias; Donald W Northfelt; Lajos Pusztai; Stacy L Moulder; Julie E Lang; Rebecca K Viscusi; David M Euhus; Barbara B Haley; Qamar J Khan; William C Wood; Michelle Melisko; Richard Schwab; Teresa Helsten; Julia Lyandres; Sarah E Davis; Gillian L Hirst; Ashish Sanil; Laura J Esserman; Donald A Berry
Journal:  N Engl J Med       Date:  2016-07-07       Impact factor: 91.245

Review 5.  Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.

Authors:  Brian M Alexander; Evanthia Galanis; W K Alfred Yung; Karla V Ballman; James M Boyett; Timothy F Cloughesy; John F Degroot; Jason T Huse; Bhupinder Mann; Warren Mason; Ingo K Mellinghoff; Tom Mikkelsen; Paul S Mischel; Brian P O'Neill; Michael D Prados; Jann N Sarkaria; Abdul Tawab-Amiri; Lorenzo Trippa; Xiaobu Ye; Keith L Ligon; Donald A Berry; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2014-08-26       Impact factor: 12.300

Review 6.  Adaptive Designs for Clinical Trials.

Authors:  Deepak L Bhatt; Cyrus Mehta
Journal:  N Engl J Med       Date:  2016-07-07       Impact factor: 91.245

Review 7.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

8.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.

Authors:  Michele Ceccarelli; Floris P Barthel; Tathiane M Malta; Thais S Sabedot; Sofie R Salama; Bradley A Murray; Olena Morozova; Yulia Newton; Amie Radenbaugh; Stefano M Pagnotta; Samreen Anjum; Jiguang Wang; Ganiraju Manyam; Pietro Zoppoli; Shiyun Ling; Arjun A Rao; Mia Grifford; Andrew D Cherniack; Hailei Zhang; Laila Poisson; Carlos Gilberto Carlotti; Daniela Pretti da Cunha Tirapelli; Arvind Rao; Tom Mikkelsen; Ching C Lau; W K Alfred Yung; Raul Rabadan; Jason Huse; Daniel J Brat; Norman L Lehman; Jill S Barnholtz-Sloan; Siyuan Zheng; Kenneth Hess; Ganesh Rao; Matthew Meyerson; Rameen Beroukhim; Lee Cooper; Rehan Akbani; Margaret Wrensch; David Haussler; Kenneth D Aldape; Peter W Laird; David H Gutmann; Houtan Noushmehr; Antonio Iavarone; Roel G W Verhaak
Journal:  Cell       Date:  2016-01-28       Impact factor: 41.582

9.  Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.

Authors:  Shyam K Tanguturi; Lorenzo Trippa; Shakti H Ramkissoon; Kristine Pelton; David Knoff; David Sandak; Neal I Lindeman; Azra H Ligon; Rameen Beroukhim; Giovanni Parmigiani; Patrick Y Wen; Keith L Ligon; Brian M Alexander
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300

10.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

  10 in total
  1 in total

1.  A platform for efficient early evaluation of biomarker-associated therapies in newly diagnosed IDH wild-type, MGMT unmethylated glioblastoma.

Authors:  Howard Colman
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.